Liubao Peng

发表

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer

Chongqing Tan, Qiao Liu, X. Luo, 2021, PloS one.

First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis.

Chongqing Tan, Liubao Peng, X. Wan, 2021, Clinical therapeutics.

A Review and Comparison of Methods for Recreating Individual Patient Data from Published Kaplan-Meier Survival Curves for Economic Evaluations: A Simulation Study

Liubao Peng, X. Wan, Yuanjian Li, 2015, PloS one.

Subgroup Economic Evaluation of Radiotherapy for Breast Cancer After Mastectomy.

Liubao Peng, X. Wan, Yuanjian Li, 2015, Clinical therapeutics.

Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study

Meiyu Wu, Chongqing Tan, X. Luo, 2022, PharmacoEconomics.

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States

Liubao Peng, X. Wan, Jianhe Li, 2021, Frontiers in Pharmacology.

Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies

Liubao Peng, X. Wan, Jianhe Li, 2021, Frontiers in Pharmacology.

Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%

Chongqing Tan, Liubao Peng, X. Wan, 2021, Advances in Therapy.

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA

Chongqing Tan, Qiao Liu, Liubao Peng, 2019, BMJ Open.

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer

Zhen Zhou, Chongqing Tan, Qiao Liu, 2022, Frontiers in Pharmacology.

Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma

Chongqing Tan, Qiao Liu, X. Luo, 2021, Advances in Therapy.

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy

Chongqing Tan, Qiao Liu, X. Luo, 2021, Frontiers in Oncology.

Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer

Chongqing Tan, Qiao Liu, X. Luo, 2021, Advances in Therapy.

Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study

Meiyu Wu, Chongqing Tan, X. Luo, 2022, PharmacoEconomics.

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

Chongqing Tan, Qiao Liu, X. Luo, 2022, Frontiers in Pharmacology.

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China

Zhen Zhou, Qiao Liu, Liubao Peng, 2022, Frontiers in Public Health.

Comparative efficacy of various CHIs combined with western medicine for non-small cell lung cancer: A bayesian network meta-analysis of randomized controlled trials

J. Chen, Liubao Peng, Jianhe Li, 2022, Frontiers in Pharmacology.

Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer

Chongqing Tan, Liubao Peng, X. Wan, 2020, Advances in Therapy.

Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China

Chongqing Tan, Liubao Peng, Lidan Yi, 2019, Advances in Therapy.

Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis

Chongqing Tan, Liubao Peng, Lidan Yi, 2021, Clinical Rheumatology.

Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Liubao Peng, X. Wan, Jianhe Li, 2021, Frontiers in Oncology.

A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer

Qiong Lu, Chongqing Tan, Liubao Peng, 2013, PloS one.

The Cost of Treating Advanced Non-Small Cell Lung Cancer: Estimates from the Chinese Experience

J. Karnon, Bin Wu, Liubao Peng, 2012, PloS one.

First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis

Chongqing Tan, Liubao Peng, X. Wan, 2019, Cancer.

First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis

Chongqing Tan, Liubao Peng, X. Wan, 2019, JAMA oncology.

Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model Analysis

Qiong Lu, Chongqing Tan, Liubao Peng, 2014, PloS one.

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

Qijian Deng, Chongqing Tan, Qiao Liu, 2021, Frontiers in Pharmacology.

Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer From the US and Chinese Perspectives.

Haijun Deng, Chongqing Tan, Liubao Peng, 2019, Clinical therapeutics.

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

Chongqing Tan, Qiao Liu, Liubao Peng, 2019, Clinical Drug Investigation.

Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure

Liubao Peng, X. Wan, Jianhe Li, 2021, Rheumatology and Therapy.

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China

Chongqing Tan, Qiao Liu, Liubao Peng, 2020, BMJ Open.

Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.

Ziying Zhao, Chongqing Tan, Liubao Peng, 2013, Clinical therapeutics.

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Chongqing Tan, Qiao Liu, Liubao Peng, 2022, Frontiers in Pharmacology.

Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China

Chongqing Tan, Liubao Peng, Lidan Yi, 2020, PloS one.

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer

Chongqing Tan, Qiao Liu, Liubao Peng, 2021, PloS one.

Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China

Liubao Peng, X. Wan, Jianhe Li, 2021, Rheumatology and Therapy.

Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States

Chongqing Tan, Qiao Liu, Liubao Peng, 2021, Advances in Therapy.

First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis

Chongqing Tan, Qiao Liu, Liubao Peng, 2021, Advances in Therapy.

Economic evaluation of nivolumab as a second‐line treatment for advanced renal cell carcinoma from US and Chinese perspectives

Liubao Peng, X. Wan, Yuanjian Li, 2017, Cancer.

PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China

Chongqing Tan, Qiao Liu, Liubao Peng, 2021, Frontiers in Oncology.

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis

Chongqing Tan, Qiao Liu, Liubao Peng, 2021, Frontiers in Pharmacology.

Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population

Chongqing Tan, Liubao Peng, Lidan Yi, 2021, Advances in Therapy.